A review of data from studies involving more than 147,000 patients was also able to rule out a 0.3% absolute increase in risk of MI with ARB treatment. Any raised risk smaller than this is unlikely to be clinically relevant, the researchers said.
Research in 2004 had suggested that ARBs may be linked to an increased MI risk.
This has been refuted by this latest analysis conducted by a team led by Dr Sripal Bangalore of New York University School of Medicine.
Reporting on the findings, the researchers said: 'In this meta-analysis we found no evidence to support the theory that ARBs increase the risk of MI. There was a significant benefit for the outcomes of stroke, heart failure, and new onset diabetes mellitus.'
However, Dr Bangalore and his team acknowledged that their analysis did not take account of doses used or compliance rates, so some clinically relevant differences in treatments may have been missed.